A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs PF 06760805 (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 02 Aug 2018 Status changed from recruiting to completed.
- 13 Feb 2018 Planned End Date changed from 13 Jun 2018 to 5 Jun 2018.
- 13 Feb 2018 Planned primary completion date changed from 13 Jun 2018 to 5 Jun 2018.